About
Cancer Apoptosis Technology
ARTSaVIT is developing a molecular mechanism of apoptosis induced by apoptotic-related tumor suppressors (ARTS). The company's goal is to determine how the binding of ARTS to inhibitors of apoptosis proteins and other apoptotic regulators causes caspase activation and cell death. Thelab currently focuses on the molecular mechanism of ARTS-induced apoptosis, therole of ARTS as a tumor suppressor in a variety of cancer models, and the development ofin-vitro and cell-based assays for the identification and screening of small-molecule ARTS mimetics that will selectively kill cancer cells and serve as anticancer drugs. ARTSaVIT operates within the framework of Merck Ventures Israel BioIncubator.
Identity
| Name | ARTSaVIT |
|---|---|
| Slug | artsavit |
| Former names | The Larisch Laboratory |
| Type / kind | startup |
| Crunchbase ID | ARTSaVIT |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwMW95ZgKDA |
Status
| Status | inactive |
|---|---|
| Status reason | Non Active, Jun 2018 ceased to operate |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Yavne |
| HQ address | HaKishon 18, Yavne, Israel |
Web & social
| Website | http://www.m-ventures.com/portfolio/artsavit |
|---|---|
| https://www.linkedin.com/company/28640260 |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Biologicals
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business models
B2B
Tags
pharmaceuticalsoncologystem-cellsbiotechnologycell-therapycancer
Funding
| Total raised | $6.3M |
|---|---|
| Current stage | Series A |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}